Format

Send to

Choose Destination
Medicine (Baltimore). 2019 Jun;98(25):e16127. doi: 10.1097/MD.0000000000016127.

Autologous whole-blood or autologous serum acupoint injection therapy for chronic urticaria: A systematic review protocol.

Author information

1
Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu.
2
The People's Hospital of Jianyang City, Jianyang.
3
Chengdu First People's Hospital.
4
Sichuan Second Chinese Medicine Hospital.
5
Clinical Medical College of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Abstract

BACKGROUND:

Chronic urticaria (CU) is a common and easily recurring skin disease in the world. Many trials have shown that autologous whole-blood or autologous serum acupoint injection therapy is effective in treating CU. There is currently no systematic review of this therapy. The program aims to evaluate the effectiveness and safety of this therapy in patients with CU.

METHODS:

Literature search will be conducted at Medline, PubMed, Excerpt Medica Database, Springer, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database, and other databases. The search date is until May 2019. We will search for popular terms including CU and this therapy. Import the literature electronically. Duplicate documents will be deleted. The primary outcome is the urticaria activity score or other validated scales. Secondary outcomes included response rate, quality of life scale, recurrence rate, and adverse events. A systematic review and search for a randomized controlled trial of this therapy for CU. Implement the Cochrane RevMan V5.3 bias assessment tool to assess bias assessment risk, data integration risk, meta-analysis risk, and subgroup analysis risk (if conditions are met). The mean difference, standard MD, and binary data will be used to represent continuous results.

RESULTS:

This study will provide a comprehensive review of the available evidence for the treatment of CU with this therapy.

CONCLUSION:

This study will provide new evidence for assessing the effectiveness and side effects of this therapy for CU. Since the data is not individualized, there is no need for formal ethical approval.

PROSPERO REGISTRATION NUMBER:

CRD42019128364.

PMID:
31232963
DOI:
10.1097/MD.0000000000016127
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center